Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dementia Discovery Fund

- PMLiVE

AbbVie and C2N take tau antibody into clinic

Treatment being assessed for a progressive neurodegenerative disorder

- PMLiVE

Roche and Evotec’s Alzheimer’s drug ineffective

Sembragiline failed to show cognitive and memory benefits

- PMLiVE

Icelandic genome study yields new disease genes

Nature Medicine study focuses on the probability of developing Alzheimer’s

Biogen Idec building

Biogen Idec claims first with Alzheimer’s candidate

Aducanumab slowed down impairment in cognition and memory in early stages

- PMLiVE

Neurodegenerative research needs better cooperation, say GlobalData

And public funding must be provided to eradicate business risks

- PMLiVE

GSK and Lilly invest in $100m global Dementia Discovery Fund

Fund announced at WHO conference by UK health secretary Jeremy Hunt

- PMLiVE

Another $2m donated to further neurodegenerative commitment

Research funders build on global initiative for brain deteriorating diseases

- PMLiVE

Dementia research alliance to fast-track new Alzheimer’s drugs

Will see Alzheimer's Research UK partner with Cambridge, Oxford and UCL universities

- PMLiVE

AB Science on track for phase III data in Alzheimer’s this year

Trial of masitinib has passed a futility test

EU flag

Pharma joins European Alzheimer’s research initiative

Lilly and Janssen among participants of dementia-focused IMI project

- PMLiVE

AZ and Lilly start BACE inhibitor trial in Alzheimer’s

Early trials show promise for the BACE inhibitor AZD3293

- PMLiVE

Charity coalition pledges millions for brain disease research

Will invest £30m developing candidates for neurodegenerative conditions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links